• Definium Therapeutics received FDA Breakthrough Therapy designation for DT120 orally disintegrating tablet in major depressive disorder.
• The designation follows results already presented from the Phase 3 Emerge study, which showed meaningful symptom improvement versus placebo.
• Benefits were described as sustained over time, supporting a potential shift toward faster-acting, durable treatment options in depression.
• DT120 is a proprietary, optimized LSD formulation; it previously secured Breakthrough Therapy designation for generalized anxiety disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609080700BIZWIRE_USPR_____20260827_BW507027) on September 08, 2026, and is solely responsible for the information contained therein.